liklihood for trading halt, page-8

Thomas, Solbec has new management and they are doing the right things as far as I can see. Their main game has got to be to get the clinical trials back on track and they cant move any faster than the TGA will allow. It may be a good idea to pick up some more SBP before too long.
I recently made a very nice return on Dendreon(NASDAQ) when they shot through the roof on a positive FDA Advisory Council meeting a positive approval vote. Analysts said it was a surprise decision, but that was no way the case. Everything the FDA had said and done over the last year pointed to that decision, but people were not paying attention. Analysts with links to short interests were giving very bad analysis that did not even make sense to me. The street went with the analysts and people with short positions were in a bind when the stock that closed at just over $5 opened up at $18 the next day. Some of those analysts are still in denial, claiming the FDA will for the first time ever will reject a treatment with a AC approval in a terminal disease. Meanwhile DNDN is hiring a night shift to work their NJ plant 24 and 7. Final approval by May 15, when the stock will surge again IMHO.
That is kind of what is happening to Solbec. Although they have early spectacular results in phase 1 trials, on very advanced patients not expected to show much efficacy, the market has not taken notice yet. Interim results from the phase 2 trial, a deal on the psorisis or cancer treatments could change the value of Solbec quickly. I have not sold a share and intend to increase my position. Chances of showing better results in the phase 2 trials, now that they have targeted the cancer where the drug showed the greatest effect, are very high in my opinion. I believe the patients will not be in such an advanced state in the phase 2 and this also increases the probability of success. In my opinion Solbec is a great buy and hold at this price. Lets see what the announcement is.